<div id="readability-page-1"><p>Maxim Group analyst Jason McCarthy has maintained their bullish  stance on <span>APRE</span> stock, giving a Buy rating today.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Jason McCarthy has given his Buy rating due to a combination of factors, including the emerging clinical profile of APR-1051 and Aprea’s solid financial position. He highlights that APR-1051, a WEE1 inhibitor, has shown early signs of anti-tumor activity, including a confirmed partial response in uterine carcinosarcoma and additional evidence of disease control, while maintaining a favorable safety and tolerability profile that compares well versus competing agents.</p> <p>He also notes that the company’s cash balance, recently strengthened by a $30M equity raise, provides sufficient runway to advance the Phase 1 program and generate further data, including at upcoming ASCO presentations. McCarthy’s model assumes eventual commercialization of APR-1051 in uterine serous carcinoma and platinum-resistant ovarian cancer, with an 80% risk adjustment applied, and he maintains a $5 price target, reflecting meaningful upside potential from current levels.</p> <p>McCarthy covers the Healthcare sector, focusing on stocks such as Moleculin Biotech, Aprea Therapeutics, and Gain Therapeutics. According to TipRanks, McCarthy has an average return of <span>-14.2%</span> and a 32.87% success rate on recommended stocks. </p> <p>In another report released today, Wedbush also reiterated a Buy rating on the stock with a $6.00 price target.</p></div>

APRE

SBIO

LABD

LABU

<p>Maxim Group analyst Jason McCarthy has reiterated a Buy rating on Aprea (APRE) stock, maintaining a $5 price target. His positive outlook is based on the promising clinical profile of APR-1051, which has shown early anti-tumor activity and a favorable safety profile. Aprea's financial position is bolstered by a recent $30M equity raise, providing a solid cash runway for advancing its Phase 1 program. Additionally, Wedbush has also issued a Buy rating with a $6 price target for the stock.</p>

Tip Ranks

Aprea Therapeutics

ALPS Medical Breakthrough

Direxion S&P Biotech Bear 3X

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Moleculin Biotech

Gain Therapeutics

Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target